查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1460612

流行病学人工智慧（AI）全球市场预测（2024-2032）

Global Artificial Intelligence (AI) in Epidemiology Market Forecast 2024-2032
出版日期: | 出版商: Inkwood Research | 英文 299 Pages | 商品交期: 2-3个工作天内

价格

主要发现

预计 2024 年至 2032 年预测期内，全球流行病学人工智慧 (AI) 市场规模的复合年增长率将达到 27.33%。 主要市场成长驱动因素包括对疾病爆发的早期检测和监测、预测疾病趋势的预测模型以及流行病学研究数据的可用性的日益增长的需求。

市场洞察

疾病爆发的早期发现和监测对于推动全球流行病学人工智慧 (AI) 市场的成长髮挥着至关重要的作用。 利用人工智慧驱动的演算法处理大量资料集，公共卫生官员可以快速识别新出现的威胁，并及时进行干预，以减轻传染病的传播。 这种积极主动的方法不仅可以挽救生命，还可以降低与治疗大规模疫情相关的医疗费用。

此外，人工智慧在流行病学领域的引入将提高疾病监测系统的效率和准确性，使得即时监测人群健康趋势成为可能。 这种能力使医疗保健利益相关者能够预测潜在的疫情、有效地分配资源并实施有针对性的干预措施，以尽量减少流行病对公共卫生和经济的影响。

人工智慧技术日益融入流行病学研究和公共卫生基础设施，将促进政府、研究机构和产业利益相关者之间的合作。 这些合作伙伴关係将促进人工智慧演算法和数据分析的创新，从而开发出更复杂的疾病检测、预测和应对工具。 因此，随着利害关係人认识到早期检测和监测在保护公众健康方面的关键作用，流行病学领域对人工智慧解决方案的需求持续飙升，推动了全球市场的成长。

区域见解

全球流行病学人工智慧 (AI) 市场成长研究彙编了欧洲、亚太地区、北美和世界其他地区的地理研究。 预计在预测期内，北美将成为全球市场的主导地区。

北美拥有先进的医疗保健基础设施，配备电子健康记录 (EHR) 等先进工具和强大的数据系统，可实现人工智慧解决方案的无缝整合和利用。 政府问责办公室 (GAO) 和美国国家医学院 (NAM) 正在合作开展一项计划，检查人工智慧/机器学习在医疗保健领域的应用，评估其影响，并确定优化其使用的关键策略。 这项措施正在显着加速人工智慧在北美流行病学市场的进展。

竞争考量

在流行病学人工智慧的竞争格局中，各公司竞相利用先进的演算法和数据分析来提供创新的解决方案，以增强疾病监测和预测。 领先的公司专注于开发强大的人工智慧模型，这些模型可以有效地分析大量医疗数据，并为公共卫生机构和医疗保健提供者提供可行的见解。

此外，与研究和政府机构的合作对于在这个快速发展的市场中获得优势至关重要。 此外，全球市场的顶尖公司还包括Epic Systems Corporation、Microsoft Corporation、Meditech等。

目录

第一章研究范围与研究方法

第 2 章执行摘要

  • 市场规模/估计
  • 市场概览
  • 调查范围
  • 危机情境分析
  • 主要市场研究结果

第三章市场动态

  • 主要驱动因素
    • 及早发现及监测疾病爆发
    • 用于预测疾病趋势的预测模型
    • 流行病学研究的数据可用性
  • 主要限制因素
    • 有关敏感患者资料的隐私和道德问题
    • 资料品质和可用性方面的课题

第四章主要分析

  • 主要市场趋势
    • 机器学习与资料分析的进展
    • 扩展远距医疗和远端监控
    • 将人工智慧融入公共卫生系统
  • 波特五力分析
  • 成长前景图
  • 市场成熟度分析
  • 市场集中度分析

第 5 章市场：依发展划分

  • 本地
    • 市场预测图表
    • 细分分析
  • 基于网路
    • 市场预测图
    • 细分分析
  • 基于云端
    • 市场预测图
    • 细分分析

第 6 章市场：依应用划分

  • 感染预测
    • 市场预测图
    • 细分分析
  • 疾病/症状监测
    • 市场预测图
    • 细分分析
  • 人口健康与发病率/盛行率监测
    • 市场预测图
    • 细分分析

第 7 章市场：依最终用途划分

  • 政府/国家机构
    • 市场预测图
    • 细分分析
  • 实验室
    • 市场预测图
    • 细分分析
  • 製药和生技公司
    • 市场预测图表
    • 细分分析
  • 医疗保健提供者
    • 市场预测图表
    • 细分分析

第 8 章区域分析

  • 北美
    • 市场规模/估计
    • 市场驱动因素
    • 市场课题
    • 市场主要参与者
    • 国家分析
  • 欧洲
    • 市场规模/估计
    • 市场驱动因素
    • 市场课题
    • 市场主要参与者
    • 国家分析
  • 亚太地区
    • 市场规模/估计
    • 市场驱动因素
    • 市场课题
    • 市场主要参与者
    • 国家分析
  • 世界其他地区
    • 市场规模/估计
    • 市场驱动因素
    • 市场课题
    • 市场主要参与者
    • 区域分析

第九章竞争态势

  • 主要策略发展
    • 併购
    • 产品发布/开发
    • 合作/协议
    • 业务扩张/缩减
  • 公司简介
    • ALPHABET INC
    • BAYER HEALTHCARE
    • CARDIOLYSE
    • CERNER CORPORATION
    • COGNIZANT
    • ECLINICAL WORKS INC
    • EPIC SYSTEMS CORPORATION
    • INTEL CORPORATION
    • KOMODO HEALTH
    • MEDITECH
    • MICROSOFT CORPORATION
    • PREDIXION HEALTHCARE（JVION LLC）
    • SAS INSTITUTE
    • SIEMENS HEALTHINEERS
Product Code: 82541

KEY FINDINGS

The global artificial intelligence (AI) in epidemiology market is forecasted to generate a CAGR of 27.33% over the projection years of 2024-2032. Key drivers facilitating the market's growth include the early detection and surveillance of disease outbreaks, the growing need for predictive modeling to forecast disease trends, and data availability for epidemiological research.

MARKET INSIGHTS

Early detection and surveillance of disease outbreaks play a pivotal role in driving the growth of the global artificial intelligence (AI) in epidemiology market. By leveraging AI-powered algorithms on vast datasets, public health authorities can swiftly identify emerging threats, enabling timely interventions to mitigate the spread of infectious diseases. This proactive approach not only saves lives but also reduces healthcare costs associated with treating widespread outbreaks.

Furthermore, the adoption of AI in epidemiology enhances the efficiency and accuracy of disease surveillance systems, enabling real-time monitoring of population health trends. This capability enables healthcare stakeholders to anticipate potential outbreaks, allocate resources effectively, and implement targeted interventions, thereby minimizing the impact of epidemics on public health and economies.

The increasing integration of AI technologies into epidemiological research and public health infrastructure fosters collaborations between governments, research institutions, and industry players. These partnerships drive innovation in AI algorithms and data analytics, leading to the development of more sophisticated tools for disease detection, prediction, and response. Consequently, the demand for AI solutions in epidemiology continues to surge, fueling the growth of the global market as stakeholders recognize the critical role of early detection and surveillance in safeguarding public health.

REGIONAL INSIGHTS

The global artificial intelligence (AI) in epidemiology market growth examination compiles the geographical study of Europe, Asia-Pacific, North America, and Rest of World. North America is set to be a major region in the global market during the forecast period.

North America boasts a sophisticated healthcare infrastructure with advanced tools like electronic health records (EHRs) and strong data systems, enabling seamless integration and use of AI solutions. The Government Accountability Office (GAO) and the National Academy of Medicine (NAM) are collaborating on an initiative to explore AI/ML applications in healthcare, assessing their impact and identifying key strategies for optimizing their use. This effort significantly accelerates progress in the North America AI in epidemiology market.

COMPETITIVE INSIGHTS

In the competitive landscape of AI in epidemiology, companies are vying to offer innovative solutions leveraging advanced algorithms and data analytics to enhance disease surveillance and prediction. Key players are focused on developing robust AI models that can efficiently analyze vast amounts of healthcare data to provide actionable insights for public health agencies and healthcare providers.

Additionally, partnerships with research institutions and government bodies are crucial for staying ahead in this rapidly evolving market. Additionally, some of the top companies in the global market are Epic Systems Corporation, Microsoft Corporation, Meditech, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. METHODOLOGY
  • 1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW
  • 2.3. SCOPE OF STUDY
  • 2.4. CRISIS SCENARIO ANALYSIS
    • 2.4.1. IMPACT OF COVID-19 ON ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • 2.5. MAJOR MARKET FINDINGS
    • 2.5.1. PUBLIC-PRIVATE PARTNERSHIP IN AI FOR HEALTH INFECTION PREDICTION & FORECASTING
    • 2.5.2. RISING APPLICATIONS OF AI IN PERSONALIZED MEDICATIONS
    • 2.5.3. INCREASING POPULARITY IN INFECTION PREDICTION AND FORECASTING ON CLOUD-BASED PLATFORMS

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. EARLY DETECTION AND SURVEILLANCE OF DISEASE OUTBREAKS
    • 3.1.2. PREDICTIVE MODELING TO FORECAST DISEASE TRENDS
    • 3.1.3. DATA AVAILABILITY FOR EPIDEMIOLOGICAL RESEARCH
  • 3.2. KEY RESTRAINTS
    • 3.2.1. PRIVACY AND ETHICAL CONCERNS REGARDING SENSITIVE PATIENT DATA
    • 3.2.2. DATA QUALITY AND AVAILABILITY CHALLENGES

4. KEY ANALYTICS

  • 4.1. KEY MARKET TRENDS
    • 4.1.1. ADVANCEMENTS IN MACHINE LEARNING AND DATA ANALYTICS
    • 4.1.2. EXPANSION OF TELEHEALTH AND REMOTE MONITORING
    • 4.1.3. INTEGRATION OF AI IN PUBLIC HEALTH SYSTEMS
  • 4.2. PORTER'S FIVE FORCES ANALYSIS
    • 4.2.1. BUYERS POWER
    • 4.2.2. SUPPLIERS POWER
    • 4.2.3. SUBSTITUTES
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. GROWTH PROSPECT MAPPING
  • 4.4. MARKET MATURITY ANALYSIS
  • 4.5. MARKET CONCENTRATION ANALYSIS

5. MARKET BY DEPLOYMENT

  • 5.1. ON-PREMISE
    • 5.1.1. MARKET FORECAST FIGURE
    • 5.1.2. SEGMENT ANALYSIS
  • 5.2. WEB-BASED
    • 5.2.1. MARKET FORECAST FIGURE
    • 5.2.2. SEGMENT ANALYSIS
  • 5.3. CLOUD-BASED
    • 5.3.1. MARKET FORECAST FIGURE
    • 5.3.2. SEGMENT ANALYSIS

6. MARKET BY APPLICATION

  • 6.1. INFECTION PREDICTION & FORECASTING
    • 6.1.1. MARKET FORECAST FIGURE
    • 6.1.2. SEGMENT ANALYSIS
  • 6.2. DISEASE & SYNDROMIC SURVEILLANCE
    • 6.2.1. MARKET FORECAST FIGURE
    • 6.2.2. SEGMENT ANALYSIS
  • 6.3. MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE
    • 6.3.1. MARKET FORECAST FIGURE
    • 6.3.2. SEGMENT ANALYSIS

7. MARKET BY END USE

  • 7.1. GOVERNMENT & STATE AGENCIES
    • 7.1.1. MARKET FORECAST FIGURE
    • 7.1.2. SEGMENT ANALYSIS
  • 7.2. RESEARCH LABS
    • 7.2.1. MARKET FORECAST FIGURE
    • 7.2.2. SEGMENT ANALYSIS
  • 7.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 7.3.1. MARKET FORECAST FIGURE
    • 7.3.2. SEGMENT ANALYSIS
  • 7.4. HEALTHCARE PROVIDERS
    • 7.4.1. MARKET FORECAST FIGURE
    • 7.4.2. SEGMENT ANALYSIS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.1.3. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.1.4. KEY PLAYERS IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.1.1. UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.1.5.2. CANADA
      • 8.1.5.2.1. CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.2.3. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.2.4. KEY PLAYERS IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. UNITED KINGDOM
      • 8.2.5.1.1. UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.2. GERMANY
      • 8.2.5.2.1. GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.3. FRANCE
      • 8.2.5.3.1. FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.4. ITALY
      • 8.2.5.4.1. ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.5. SPAIN
      • 8.2.5.5.1. SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.6. REST OF EUROPE
      • 8.2.5.6.1. REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.3. ASIA-PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.3.3. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.3.4. KEY PLAYERS IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.1.1. CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.2. JAPAN
      • 8.3.5.2.1. JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.3. INDIA
      • 8.3.5.3.1. INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.4. SOUTH KOREA
      • 8.3.5.4.1. SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.5. AUSTRALIA & NEW ZEALAND
      • 8.3.5.5.1. AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.6. REST OF ASIA-PACIFIC
      • 8.3.5.6.1. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.4.3. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.4.4. KEY PLAYERS IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.1.1. LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.4.5.2. MIDDLE EAST & AFRICA
      • 8.4.5.2.1. MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGERS & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 9.1.3. PARTNERSHIPS & AGREEMENTS
    • 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
  • 9.2. COMPANY PROFILES
    • 9.2.1. ALPHABET INC
      • 9.2.1.1. COMPANY OVERVIEW
      • 9.2.1.2. PRODUCT LIST
      • 9.2.1.3. STRENGTHS & CHALLENGES
    • 9.2.2. BAYER HEALTHCARE
      • 9.2.2.1. COMPANY OVERVIEW
      • 9.2.2.2. PRODUCT LIST
      • 9.2.2.3. STRENGTHS & CHALLENGES
    • 9.2.3. CARDIOLYSE
      • 9.2.3.1. COMPANY OVERVIEW
      • 9.2.3.2. PRODUCT LIST
      • 9.2.3.3. STRENGTHS & CHALLENGES
    • 9.2.4. CERNER CORPORATION
      • 9.2.4.1. COMPANY OVERVIEW
      • 9.2.4.2. PRODUCT LIST
      • 9.2.4.3. STRENGTHS & CHALLENGES
    • 9.2.5. COGNIZANT
      • 9.2.5.1. COMPANY OVERVIEW
      • 9.2.5.2. PRODUCT LIST
      • 9.2.5.3. STRENGTHS & CHALLENGES
    • 9.2.6. ECLINICAL WORKS INC
      • 9.2.6.1. COMPANY OVERVIEW
      • 9.2.6.2. PRODUCT LIST
      • 9.2.6.3. STRENGTHS & CHALLENGES
    • 9.2.7. EPIC SYSTEMS CORPORATION
      • 9.2.7.1. COMPANY OVERVIEW
      • 9.2.7.2. PRODUCT LIST
      • 9.2.7.3. STRENGTHS & CHALLENGES
    • 9.2.8. INTEL CORPORATION
      • 9.2.8.1. COMPANY OVERVIEW
      • 9.2.8.2. PRODUCT LIST
      • 9.2.8.3. STRENGTHS & CHALLENGES
    • 9.2.9. KOMODO HEALTH
      • 9.2.9.1. COMPANY OVERVIEW
      • 9.2.9.2. PRODUCT LIST
      • 9.2.9.3. STRENGTHS & CHALLENGES
    • 9.2.10. MEDITECH
      • 9.2.10.1. COMPANY OVERVIEW
      • 9.2.10.2. PRODUCT LIST
      • 9.2.10.3. STRENGTHS & CHALLENGES
    • 9.2.11. MICROSOFT CORPORATION
      • 9.2.11.1. COMPANY OVERVIEW
      • 9.2.11.2. PRODUCT LIST
      • 9.2.11.3. STRENGTHS & CHALLENGES
    • 9.2.12. PREDIXION HEALTHCARE (JVION LLC)
      • 9.2.12.1. COMPANY OVERVIEW
      • 9.2.12.2. PRODUCT LIST
      • 9.2.12.3. STRENGTHS & CHALLENGES
    • 9.2.13. SAS INSTITUTE
      • 9.2.13.1. COMPANY OVERVIEW
      • 9.2.13.2. PRODUCT LIST
      • 9.2.13.3. STRENGTHS & CHALLENGES
    • 9.2.14. SIEMENS HEALTHINEERS
      • 9.2.14.1. COMPANY OVERVIEW
      • 9.2.14.2. PRODUCT LIST
      • 9.2.14.3. STRENGTHS & CHALLENGES

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY
  • TABLE 2: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DEPLOYMENT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 3: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DEPLOYMENT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 4: GLOBAL ON-PREMISE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 5: GLOBAL ON-PREMISE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 6: GLOBAL WEB-BASED MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 7: GLOBAL WEB-BASED MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 8: GLOBAL CLOUD-BASED MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 9: GLOBAL CLOUD-BASED MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 10: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 11: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 12: GLOBAL INFECTION PREDICTION & FORECASTING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 13: GLOBAL INFECTION PREDICTION & FORECASTING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 14: GLOBAL DISEASE & SYNDROMIC SURVEILLANCE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 15: GLOBAL DISEASE & SYNDROMIC SURVEILLANCE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 16: GLOBAL MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 17: GLOBAL MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 18: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY END USE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 19: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY END USE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 20: GLOBAL GOVERNMENT & STATE AGENCIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 21: GLOBAL GOVERNMENT & STATE AGENCIES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 22: GLOBAL RESEARCH LABS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 23: GLOBAL RESEARCH LABS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 24: GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 25: GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 26: GLOBAL HEALTHCARE PROVIDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 27: GLOBAL HEALTHCARE PROVIDERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 28: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 29: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 30: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 31: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 32: KEY PLAYERS OPERATING IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 33: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 34: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 35: KEY PLAYERS OPERATING IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 36: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 37: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 38: KEY PLAYERS OPERATING IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 39: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 40: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 41: KEY PLAYERS OPERATING IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 42: LIST OF MERGERS & ACQUISITIONS
  • TABLE 43: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 44: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 45: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: GROWTH PROSPECT MAPPING
  • FIGURE 4: MARKET MATURITY ANALYSIS
  • FIGURE 5: MARKET CONCENTRATION ANALYSIS
  • FIGURE 6: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY DEPLOYMENT, IN 2023
  • FIGURE 7: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY ON-PREMISE, 2024-2032 (IN $ MILLION)
  • FIGURE 8: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY WEB-BASED, 2024-2032 (IN $ MILLION)
  • FIGURE 9: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY CLOUD-BASED, 2024-2032 (IN $ MILLION)
  • FIGURE 10: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023
  • FIGURE 11: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY INFECTION PREDICTION & FORECASTING, 2024-2032 (IN $ MILLION)
  • FIGURE 12: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DISEASE & SYNDROMIC SURVEILLANCE, 2024-2032 (IN $ MILLION)
  • FIGURE 13: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE, 2024-2032 (IN $ MILLION)
  • FIGURE 14: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY END USE, IN 2023
  • FIGURE 15: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GOVERNMENT & STATE AGENCIES, 2024-2032 (IN $ MILLION)
  • FIGURE 16: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY RESEARCH LABS, 2024-2032 (IN $ MILLION)
  • FIGURE 17: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2024-2032 (IN $ MILLION)
  • FIGURE 18: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY HEALTHCARE PROVIDERS, 2024-2032 (IN $ MILLION)
  • FIGURE 19: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 20: UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 21: CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 22: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 23: UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 24: GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 25: FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 26: ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 27: SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 28: REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 29: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 30: CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 31: JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 32: INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 34: AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 35: REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 36: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 37: LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 38: MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)